Abstract
Macroeconomic variables primarily related to the health care system are the result of two key factors. On the one hand, the results obtained for preserving the health of individuals improving, also, the quality of life and, on the other hand, the costs to be supported in order to reach these results. There is evidence that a balance between these two parameters must be obtained in an era of limited economic resources and, therefore, measures, which can achieve these variables, are under study.
Cost-effectiveness ratio is the most economic factor analyzed still lending to define the relationship between costs and disease. With regard to cardiovascular risk, budgets not always in line with established expectations are under exam.
Quantitative measures related to cost-effectiveness ratio as the estimate-score system, which sets specific scores for the symptoms of the disease, are studied to improve the budget that regulates costs and results on public health including cardiovascular risk characterized by a high frequency of adverse events.
Keywords: Economic costs, cost-effectiveness ratio, cardiovascular risk, health care system, budgets, parameters, estimate-score system, economic resources, balance, parameters
Current Pharmaceutical Design
Title:The Economic Costs for the Control of Cardiovascular Risk: An Overview
Volume: 19 Issue: 13
Author(s): Aldo Leone
Affiliation:
Keywords: Economic costs, cost-effectiveness ratio, cardiovascular risk, health care system, budgets, parameters, estimate-score system, economic resources, balance, parameters
Abstract: Macroeconomic variables primarily related to the health care system are the result of two key factors. On the one hand, the results obtained for preserving the health of individuals improving, also, the quality of life and, on the other hand, the costs to be supported in order to reach these results. There is evidence that a balance between these two parameters must be obtained in an era of limited economic resources and, therefore, measures, which can achieve these variables, are under study.
Cost-effectiveness ratio is the most economic factor analyzed still lending to define the relationship between costs and disease. With regard to cardiovascular risk, budgets not always in line with established expectations are under exam.
Quantitative measures related to cost-effectiveness ratio as the estimate-score system, which sets specific scores for the symptoms of the disease, are studied to improve the budget that regulates costs and results on public health including cardiovascular risk characterized by a high frequency of adverse events.
Export Options
About this article
Cite this article as:
Leone Aldo, The Economic Costs for the Control of Cardiovascular Risk: An Overview, Current Pharmaceutical Design 2013; 19 (13) . https://dx.doi.org/10.2174/1381612811319130013
DOI https://dx.doi.org/10.2174/1381612811319130013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Genome-wide Association Analysis in Four Populations Reveals Strong Genetic Heterogeneity For Birth Weight
Current Genomics Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Anti-Atherosclerotic Therapy Based on Botanicals
Recent Patents on Cardiovascular Drug Discovery Management of Peyronie's Disease after Collagenase (Xiaflex:<sup>®</sup>)
Current Drug Targets Barriers to Achieving Optimal Glycemic Control in a Multi-Ethnic Society: A US Focus
Current Diabetes Reviews Effects of Statins on Transplant Graft Arterial Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Impact of Uncontrolled Hypertension on the Longitudinal Systolic Function of the Left Ventricle
Current Hypertension Reviews Cytokine Gene Variants as Predictors of Type 2 Diabetes Mellitus
Current Diabetes Reviews Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents ENaC Regulation by Proteases and Shear Stress
Current Molecular Pharmacology Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine Sevoflurane in Intraoperative and Postoperative Cardiac Surgery Patients. Our Experience in Intensive Care Unit with Sevoflurane Sedation
Current Pharmaceutical Design Secondary Prevention of Ischemic Stroke
Current Drug Targets Is Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?
Current Pharmaceutical Design Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Neuroprotective Actions of Flavones and Flavonols: Mechanisms and Relationship to Flavonoid Structural Features
Central Nervous System Agents in Medicinal Chemistry Radionuclide PET and PET/CT in Coronary Artery Disease
Current Pharmaceutical Design Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry